NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD
Overall HALO gets a fundamental rating of 8 out of 10. We evaluated HALO against 555 industry peers in the Biotechnology industry. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HALO is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, HALO could be worth investigating further for value and growth and quality investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 22.1% | ||
ROE | 100.64% | ||
ROIC | 23.44% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 55.1% | ||
PM (TTM) | 44.76% | ||
GM | 83.45% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 3.13 | ||
Debt/FCF | 3.04 | ||
Altman-Z | 4.63 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.39 | ||
Quick Ratio | 7.3 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 11.83 | ||
Fwd PE | 7.26 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 13.38 | ||
EV/EBITDA | 10.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
53.84
+0.92 (+1.74%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 11.83 | ||
Fwd PE | 7.26 | ||
P/S | 6.12 | ||
P/FCF | 13.38 | ||
P/OCF | 13.17 | ||
P/B | 13.76 | ||
P/tB | N/A | ||
EV/EBITDA | 10.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 22.1% | ||
ROE | 100.64% | ||
ROCE | 29.2% | ||
ROIC | 23.44% | ||
ROICexc | 36.94% | ||
ROICexgc | 96.44% | ||
OM | 55.1% | ||
PM (TTM) | 44.76% | ||
GM | 83.45% | ||
FCFM | 45.72% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 3.13 | ||
Debt/FCF | 3.04 | ||
Debt/EBITDA | 2.22 | ||
Cap/Depr | 9.93% | ||
Cap/Sales | 0.75% | ||
Interest Coverage | 250 | ||
Cash Conversion | 74.2% | ||
Profit Quality | 102.14% | ||
Current Ratio | 8.39 | ||
Quick Ratio | 7.3 | ||
Altman-Z | 4.63 |